Feedback Share Discussion Threads

[ged5] 01/4/2020 10:18

From LR2's post 4882, I hope you don't mind me re-posting the link. I think it was missed on Friday afternoon:-

Project

Imaging COVID-19 AI initiative is a multicenter European project to enhance computed tomography (CT) in the diagnosis of COVID-19 by using artificial intelligence. The project group will create a deep learning model for automated detection and classification of COVID-19 on CT scans, and for assessing disease severity in patients by quantification of lung involvement.

Many different hospitals and institutions across Europe will collaborate to rapidly develop an artificial intelligence solution in this time-sensitive research project. The AI model will be made freely available to all participants for clinical validation.




WHY AI?

To be able to cope with the growing number of COVID-19 patients, it is necessary to find ways to help doctors in their fight against the virus. In these dramatic circumstances the value of AI comes into play, by reducing the burden on clinicians. While a manual read of a CT scan can take up to 15 minutes, AI can analyze the images in 10 seconds.

Therefore, automated image analysis with artificial intelligence techniques has the potential to optimize the role of CT in the assessment of COVID-19 by allowing accurate and fast diagnosis of infection in a large number of patients. AI has the potential to support clinical decision making and improve workflow efficiency.

[ged5] 01/4/2020 10:06

Could TexRAD be used? Remind me, what's happening with TexRAD Lung?

TexRAD is in very many institutions across the world, some very prestigious one's. Italy, South Korea, India, US among the many.

OK FDBK are concentrating on Bleepa but surely someone, somewhere will see it's use.

TexRAD isn't dead.

[lr2] 31/3/2020 14:01

I guess it's only fair for you to let someone else have a go.

[davydoo] 31/3/2020 13:59

not me guv

[lr2] 31/3/2020 13:55

Anyone want to own up to those 2 x 1 mil buys this morning? Davy?

[ducatiman] 31/3/2020 13:06

I wonder if there will be an RNS?

[ged5] 31/3/2020 10:18

Join us for our Livestream at 9:30am Friday 3rd April with Dr Tom Oakley:
Tackling #COVID19 On All Fronts: How can remote imaging tech be utilised to support the frontline during the Coronavirus crisis, reducing the number of people exposed?



At least he keeps trying! I think we all just want to see Bleepa being adopted by several trusts.

[ged5] 30/3/2020 15:07

Tweet from Bleepa



Link to Hassan Chaudhury's full post.



Who?

Hassan Chaudhury
Digital Health Lead at Healthcare UK, Department for International Trade

[lr2] 29/3/2020 20:41

Feedback offers Bleepa for COVID-19 use
By Andrew Hore - 29/03/2020

Feedback (LON: FDBK) is offering its Bleepa medical imaging communications platform to help with COVID-19. Hospitals will be able to use it for free.

Bleepa was launched last July. It can be used to transmit encrypted data between a hospital and a clinician’s own device when they are away from the hospital. Images, such as x-rays, CT scans and ultrasound scans can be sent.

In the case of COVID-19, images of the lungs of patients can be transmitted. The image quality means that important decisions can be made from these images.

Bleepa uses Feedback’s Cadran picture archiving and communications system. There is also an encrypted messaging function.

Bleepa is the main focus for Feedback and it offers the potential for significant recurring revenues.

AIM-quoted Feedback secured the first pilot study for Bleepa with The Pennine Acute Hospitals NHS Trust, which has been using Bleepa for respiratory requests. This pilot was near to completion, but it has been suspended for the time being.

Self-isolation

One of the attractions of Bleepa is that it can be used by clinicians that are self-isolating. They can continue to help with diagnosis. The whole team can be in different locations and still be able to work together.

There has been a significant increase in chest x-rays and CT scans. These can be assessed via Bleepa and there is no concern about security.

This will help to make clinicians aware of the effectiveness of Bleepa and how it can be helpful at any time.

The Feedback share price has been highly volatile. There was a jump in the share price, but it fell back to 0.65p.

[yump] 29/3/2020 15:47

phurley

I have the same issue as you I think. Although Bleepa is on the face of it a simple sell, not yet sure whether that makes it any more likely than a complex medical device, to get sales into the NHS.

In theory it should be easier, purely because it won't need all the peer reviews, the NICE approvals etc. etc. that many other devices need. Not that they necessarily help anyway !

As far as I'm aware, the main problems are getting concensus in any size for more than a handful of departments to use something, combined with the time taken to get even the smallest budget for it.

Surely sooner or later the phrase 'its different this time' might apply...

[ged5] 28/3/2020 14:06

Just read on the BBC website:-

South Korea says for the first time it has more people who have recovered than are infected.

They have far fewer tested positive than several countries



Is there any connection that they could identify coronavirus quicker because they had the right tools?

Feedback plc (AIM: FDBK, "Feedback" or the "Company"), the specialist medical imaging technology company, announces that its operating company Feedback Medical Ltd has received an order from its South Korean distributor for TexRAD®, its patented image texture analysis technology, for the Samsung Medical Centre in Seoul.

The order came via Feedback's South Korean distributor, Korea Computer Motion ISG ("Korea ISG"). It follows the exclusive distributor arrangement announced on 8 June 2017 granting Korea ISG the ability to sell and distribute TexRAD® in South Korea for research purposes, performing advanced analysis of routinely acquired medical diagnostic images, such as CT and MRI scans.

To date, Korea ISG has obtained several orders for Feedback's TexRAD® software technology in South Korea. This is the first order from Samsung Medical Centre, one of the nation's leading hospital groups, founded by Samsung Group. Samsung Medical Centre has a strong focus on research, particularly in radiology and oncology.

[ged5] 27/3/2020 18:22

Sorry! I missed this somehow:-

From a governance perspective Bleepa is a secure, encrypted, zero footprint application meaning that no patient data is stored locally on any device. It is manufactured according to the ISO 13485 quality standard and is the only communication platform to be certified as a Class 1 CE marked device for undertaking medical image review.

[ged5] 27/3/2020 18:11

Looking on the map on this page most of the countries mentioned in the article have some use of TexRAD.



Nearly 50m yesterday as well, Davy.

Have a good weekend and stay safe. No need to go out now. The amorous one remembered she was in the Wine Club and ordered plenty of wine and beer! We've got enough until it arrives.

[ged5] 27/3/2020 18:06

Looks tailor made for TexRAD, LR2

...images displayed on Bleepa are certified as being of clinical review quality in compliance with CE marking and RCR guidelines.

With PCR testing having low sensitivity, and taking 8 hours to yield a result, CXR and CT imaging are becoming the primary diagnostic tools in the coronavirus outbreak. This does however create a significant problem for healthcare providers:

There are not enough Radiologists to report coronavirus studies in addition to existing non coronavirus case reporting commitments.

This shortfall can be infilled by consultant physicians and senior registrars who are able to interpret basic scans. However, as both radiologists and clinicians are forced to self-isolate there will be an increasing need for remote access to imaging software in order to undertake this work from home. Some Radiologists are able to undertake reporting from home through Trust devices linked via VPN connections to core hospital networks however this is not scalable in the short term and will not be able to cope with the number of clinicians who will need access from home, there are not enough Trust devices and the VPNs are too cumbersome to enable workflow at this volume.




If the images are certified it can't be long before we get an announcement.

[davydoo] 27/3/2020 18:05

81m shares traded! A huge proportion of free float. Unless of course it was the same shares being bounced back and forth between traders

[lr2] 27/3/2020 16:54

Interesting Covid-19 imaging webpage. I wonder if TexRAD should be part of this.

[iamgreat1] 27/3/2020 16:34

P n d complete by tops and the gang

[phurley] 27/3/2020 15:55

The product is great. It is a solution that the NHS is crying out for. Yes its in a better position.I just have doubts they can get a decent contract from Trusts. I hope I am proved wrong.

[yump] 27/3/2020 15:42

What's that saying about a monkey, a typewriter and the works of Shakespeare ?

Only it appears that simple sentences are a problem here for some humans.

[iamgreat1] 27/3/2020 15:30

Freee nonrevenue It can all the exposure The pump is almost over Tops and gang have moved on

[yump] 27/3/2020 12:37

1. The only difference here is that Bleepa is going to get more exposure.
2. Getting any exposure at all, whether free or not, is very difficult in the NHS.
3. The pilot generated no revenue.
4. The free use will generate no revenue, so the issue of 'no revenue' is irrelevant.

The issue is whether the free and increased use costs FDBK more and if it does, how much and is that worthwhile given the increased exposure, which in effect is a more rapid trial.

If the app. has fixed costs and is infinitely scalable, that would be great. I don't know.

Nobody here knows the answer to that.
Put up or shut up comes to mind.

Its a simple question: is FDBK now in a better position than before ?

[petekand] 27/3/2020 12:28

Iamgreat
If the ‘gang’ have moved on, I suggest you now do the same and leave some of us long-suffering holders in peace. Thank you in advance.